Podcasts

September 2020

Long term exposure to momelotinib in JAK inhibitor naïve and previously JAK inhibitor treated intermediate or high risk myelofibrosis patients

SUBSCRIBE TO BJH HEMATALKS SERIES

Latest podcasts

September 2024

Exploring Second-Generation BTK Inhibitors in Chronic Lymphocytic Leukemia (CLL)

Dr. Adam Kittai (Icahn School of Medicine, Mount Sinai, New York)

January 2024

PODCASTS

Dr Deeren discusses the latest update in the management of patients with Paroxysmal Nocturnal Hemoglobinuria including the place of the new long acting C5 inhibitor ravulizumab in the treatment algorithm

Dr. Dries Deeren (AZ Delta, Roeselare)

September 2023

Prof. Paolo Ghia discusses the results of a matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia

Prof. Paolo Ghia (Università Vita Salute San Raffaele, Italy)

Top